Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$158K Sell
11,376
-443
-4% -$6.91K ﹤0.01% 1842
2026
Q1
$149K Buy
11,819
+125
+1% +$1.27K ﹤0.01% 1760
2025
Q4
$102K Buy
11,694
+561
+5% +$4.87K ﹤0.01% 1596
2025
Q3
$104K Sell
11,133
-3,385
-23% -$31.5K ﹤0.01% 1600
2025
Q2
$130K Buy
+14,518
New +$116K ﹤0.01% 1548
2024
Q4
Sell
-10,419
Closed -$61.8K 1440
2024
Q3
$61.8K Sell
10,419
-40,968
-80% -$228K ﹤0.01% 1390
2024
Q2
$270K Buy
51,387
+8,127
+19% +$41.4K 0.01% 1162
2024
Q1
$235K Sell
43,260
-2,399
-5% -$15.3K ﹤0.01% 1140
2023
Q4
$335K Buy
45,659
+15,663
+52% +$103K 0.01% 955
2023
Q3
$247K Buy
+29,996
New +$267K 0.01% 1015

Other funds holding ADTN

Vident Advisory's ADTN Position: Q2 2026 in Review

Vident Advisory reduced its Adtran (ADTN) stake by 3.7% in Q2 2026, selling an estimated $6.91K and leaving 11,376 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Vident Advisory first reported a position in ADTN in Q3 2023 and has held it in 10 quarters since. The position peaked at $335K in Q4 2023. 249 funds tracked by Wall St. Rank hold ADTN as of Q2 2026.

  • Vident Advisory held 11,376 shares of Adtran worth $158K as of Q2 2026.
  • Vident Advisory sold 443 Adtran shares in Q2 2026, an estimated $6.91K.
  • Adtran made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1842 holding.
  • Vident Advisory first reported a position in Adtran in Q3 2023 and has held it in 10 quarters since.
  • Vident Advisory's Adtran position peaked at $335K in Q4 2023.
  • 249 funds tracked by Wall St. Rank held Adtran as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.